logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2018—No compelling benefit of oral napabucasin for advanced gastric and gastroesophageal junction adenocarcinoma

Oral napabucasin was thought to target cancer stem cells.